GEMOGENOVATUCEL-T

Non-Small Cell Lung Carcinoma

Gradalis, Inc.Cell therapyPhase 2Dormant

B

56/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 41/ 100
Competitive Position: 81/ 100

Competitive context

1128 Active assets in the Non-Small Cell Lung Carcinoma cohort.

Asset / Sponsor	Phase	Rating
Necitumumab Jonsson Comprehensive Cancer Center	Phase 3	BBB
Glumetinib Shanghai JMT-Bio Inc.	Phase 3	BBB
Veliparib AbbVie	Phase 3	BBB
d-0316 Betta Pharmaceuticals Co., Ltd.	Phase 2/3	BBB
Icotinib The First Affiliated Hospital of Guangzhou Medical University	Phase 4	BBB

View all 50 →

Same molecule, other indications

GEMOGENOVATUCEL-T is also rated in:

uterine cancerDormant

B

Indicative · Phase 2

57 / 100

Ewing sarcomaDormant

B

Indicative · Phase 3

57 / 100

Ewing sarcoma/peripheral primitive neuroectodermal tumorDormant

B

Indicative · Phase 3

56 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.